Introduction
Pancreatic cystic lesions (PCLs) are commonly identified due to increased use of cross-sectional imaging in patients with nonspecific abdominal complaints. The majority of PCLs are inflammatory pseudocysts. Although cystic neoplasms account for approximately 10% of PCLs, management remains difficult because of the challenges in unequivocal cyst characterization as well as the uncertain natural history of neoplastic cysts. Among neoplasms, serous cystadenomas (SCAs), mucinous cystadenomas (MCAs), and intraductal papillary mucinous neoplasms (IPMNs) account for 90%; the mucinous types are the key lesions with risk of malignancy [1, 2] . Therefore, diagnostic methods to improve the differentiation between benign from (pre)-malignant as well as neoplastic from nonneoplastic lesions remain a source of active investigation.
Epidemiology
A report found that the prevalence of incidental pancreatic cysts seen on multidetector computed tomography (MDCT) was 2.6%. Cysts were strongly associated with increasing age and Asian race [3] . Ishikawa et al. [4] found that the prevalence of PCLs including IPMNs among patients on hemodialysis was higher than normal population.
PCLs may occasionally cause abdominal pain, pancreatitis, or obstructive jaundice, but most are asymptomatic. Recent studies, evaluating the natural history of incidental PCLs, demonstrated that the vast majority of asymptomatic pancreatic cysts without concerning clinical or imaging features could be followed safely without surgery [5 ,6] .
Buscaglia et al. [7 ] developed a predictive model for cyst malignancy to improve selection for surgical resection. White patients above 50 years old presenting with weight loss and cyst size of more than 1.5 cm had 6-fold higher likelihood of having malignancy than patients without these factors. They confirmed the value of a very high cyst carcinoembryonic antigen (CEA) as a predictor of malignancy. The results of this study were in agreement with the findings that older age, male gender, and malignant cytology from endoscopic ultrasound (EUS) predict malignancy at surgical resection in another series [8] . Cadili et al. [9] demonstrated that overall survival in patients with neoplastic pancreatic cysts is determined by patient factors (i.e. age and sex) rather than factors descriptive of the cyst such as size and morphology.
Cross-sectional imaging
There is significant variability in the appearance of serous and mucinous neoplasms. Several authors have reported the limited value of transabdominal ultrasound, CT, and MRI for differentiating SCAs (especially its macrocystic variant) from mucinous lesions [1] . More recently, Kim et al. [10] assessed CT features to distinguish benign from premalignant and malignant lesions in macrocystic pancreatic cysts. They report that lobulated shape, thin wall, and smooth internal surface were more frequent in benign cysts, whereas round or oval shape or complex cystic shape with tubular cyst, thick wall, and an irregular internal surface were more frequent in premalignant and malignant cysts. When MDCT was compared with MRI-magnetic resonance cholangiopancreatography (MRCP) in characterizing small pancreatic cysts ( 3 cm), the accuracy was higher in classifying cysts as mucinous or nonmucinous than determining a specific diagnosis (71-84.2% vs. 39.5-44.7%, respectively). The accuracy of the two techniques in characterizing cysts into nonaggressive and aggressive categories was similar (MDCT vs. MRI, 75-78% vs. 78-86%, respectively, P > 0.05). A different report suggests MRI may be slightly better for the assessment of the morphology of small cysts than MDCT [11] . These recent data continue to confirm the limitations of imaging alone for PCL characterization.
Endoscopic ultrasound
EUS provides high-resolution images of cyst morphology and can obtain cyst fluid by fine needle aspiration (FNA). The diagnostic accuracy of EUS morphology alone for PCLs varies between 51 and 73% in different studies [1, 2] .
Endosonographic features like the presence of a solid component associated with the cyst (Fig. 1) , mural nodule, associated mass (Fig. 2) , cyst size of more than 3 cm, dilated pancreatic duct, and lymphadenopathy usually suggest premalignant or malignant lesions. However, interobserver agreement among experienced endosonographers is moderately good in the presence or absence of solid component only but not for other EUS features. EUS alone, like other imaging tests, is inadequate in characterizing PCLs [12] . Therefore, EUS-guided FNA (EUS-FNA) for cyst fluid analysis remains an important addition to further characterize PCLs. Antillon et al. [13] recently reported a case of EUS-assisted biopsy of the wall of a large cyst that confirmed a pseudocyst ; however, this approach would not be useful for most of the small indeterminate cystic lesions.
Cyst fluid cytology
Cytologic examination of cyst fluid is insensitive due to the few cells present. In an attempt to improve diagnostic accuracy of cytology, the EchoBrush, a disposable cytologic brush for FNA was developed. Bruno et al. [14] recently reported their experience in 39 patients (12 with solid pancreatic masses, 12 with pancreatic cysts, seven with enlarged lymph nodes, and eight with submucosal masses). The material collected with the EchoBrush and with a standard FNA needle was evaluated by two blinded cytopathologists. Adequate material for cytologic analysis was collected in 17 of 39 patients (43.6%) with a single pass of the EchoBrush. Results were better for pancreatic lesions (for solid and cystic lesions, the adequacy was 58.3 and 50%, respectively); adequacy was low (28.6 and 25%, respectively) for lymph nodes and submucosal masses. The overall sensitivity and specificity was poor; there were no adverse events with the procedure. A low concentration of lipase is seen in SCAs and in the majority of mucinous cystic neoplasms (MCNs). However, there seems to be an overlap of cyst fluid amylase and lipase levels between the different types of PCLs [1] . Therefore, the use of fluid amylase and lipase can be misleading.
Several studies have attempted to differentiate mucinous from nonmucinous lesions by measuring levels of different glycoprotein markers, such as CEA, carbohydrate antigen (CA) 19-9, CA 72-4, and CA 15-3 from aspirated cyst fluid. Although reviews suggest that cyst fluid CEA, CA 72-4, CA 19-9, and cytology are useful tools in distinguishing SCAs, MCNs, and nontumorous cysts [15] , CEA appears be the most useful marker in differentiating mucin from nonmucin producing tumors [16] . A CEA level of more than 192 ng/ml had an accuracy of 79% for accurate mucinous lesion characterization and was superior to cytology, EUS morphology, and all combined together in a large multicenter study. Walsh et al. [17] confirmed that asymptomatic patients with cyst fluid lacking mucin and CEA of more than 200 ng/ml do not harbor a mucinous neoplasm requiring resection within 2 years of follow-up. Leung et al. [18] confirmed the value of a thick cyst wall or intracystic growth, elevated cyst fluid CEA, in their retrospective review of EUS at a cancer referral center. They propose assessing cyst fluid viscosity with a 'string sign' that associated with premalignant or malignant cysts. This surrogate, like CEA, was imperfect in characterization of PCLs and alone cannot be used to diagnose the nature of the lesion with certainty.
Molecular analysis of cyst fluid
A recently published multicenter study, called the PANDA (pancreatic cyst fluid DNA analysis) study, demonstrated a strong association of mucinous cystic neoplasms with K-ras mutations occurring with other loss of heterozygosity (LOH) mutations [19 ] . Shen et al. [20] assessed the correlation between this commercially available molecular diagnosis with a clinical consensus diagnosis for malignant, benign mucinous, and benign nonmucinous pancreatic cysts. The consensus diagnosis was defined by histology, malignant cytology, or two concordant tests (such as EUS, cytology, or CEA !192 ng/ml for mucinous cysts). The molecular diagnosis included analysis of K-ras mutation, LOH, and quantity/ quality of DNA. The study showed that the two diagnostic methods correlated well and molecular analysis of pancreatic cyst fluid added diagnostic value to the preoperative diagnosis with high sensitivity, specificity, and positive predictive value for the diagnosis of malignant and benign mucinous pancreatic cysts.
In contrast, comparative analysis of pancreatic cyst fluid CEA and DNA mutational analysis in the detection of mucinous or malignant cysts in two other studies showed poor agreement between CEA levels and molecular analysis for diagnosis of mucinous cysts [21, 22] . Diagnostic sensitivity, however, was improved when results of CEA levels and molecular analysis were combined. In the detection of malignant cysts, elevated CEA levels were more predictive of histology in comparison to K-ras-2 or LOH mutations. Additionally, false positivity of LOH mutations was noted to be considerably higher than K-ras-2 mutations or even fluid CEA levels. These findings suggest that DNA mutation analysis should not be used routinely, but rather very selectively in the evaluation of pancreatic cysts [22] . Cyst fluid DNA analysis can provide us additional clinically meaningful information to justify the effort and cost of the test in only highly selected circumstances and should not be used routinely [23 ] .
Cyst fluid biomarkers
In an attempt to differentiate serous from premalignant mucinous cysts, researchers have investigated the pattern of biomarker expression. Using a commercially available custom-designed multiplex assay and studying aspirates of lesions at the time of surgery, they found the majority of proteins were downregulated in IPMN and MCN compared with SCA. The only proteins significantly overexpressed in mucinous cysts were CEA and CA 72-4. They report that using multimarker sample classification, they could accurately discriminate between SCAs and IPMNs in 92% of patients [24] ; further studies in nonselected patient populations are awaited.
In addition, preliminary work on biomarkers using proteomic analysis in order to improve diagnostic accuracy was reported. A panel of potential biomarker proteins that correlated with CEA including two homologs of amylase, solubilized molecules of four mucins, four solubilized CEA-related cell adhesion molecules (CEACAMs), and four S100 homologs. This approach required less than 40 ml of cyst fluid per sample, offering the possibility to analyze cysts smaller than 1 cm in diameter [25] . These preliminary reports appear worthy of further study.
Endoscopic retrograde pancreatography
With the advent of EUS and MRCP, the role of endoscopic retrograde pancreatography (ERP) in the evaluation of PCLs has become limited to evaluation of suspected IPMNs. Communication between the main pancreatic duct and a cyst, an important characteristic of IPMNs, may not be apparent on EUS. MRCP is a noninvasive method to evaluate ductal communication of a cyst when EUS is inconclusive. ERP is not useful in evaluation of SCAs and MCNs because these lesions do not communicate with the main pancreatic duct. In IPMN, a side-viewing duodenoscope may show the pathognomonic finding of mucus extruding from a patulous pancreatic orifice. In addition, pancreatoscopy with or without biopsy can be helpful for main duct disease [1] .
Management of pancreatic cystic lesions
Despite improvements in imaging and evaluation of cyst contents with biochemical as well as molecular profiling, accurate preoperative diagnosis remains elusive. This leads to uncertainty for patients and clinicians and the advocacy for surgical resection in all patients fit for surgery.
In 2004, a set of expert consensus guidelines was published for the management of mucinous cystic lesions of the pancreas [26] . It recommends that all patients, even if asymptomatic, be considered for surgical resection. It outlines an approach to evaluation and surveillance based on lesion type and size. The Johns Hopkins group sought to assess physician awareness of these guidelines and characterized practice habits [27 ] . Although the low rate of survey response is a major limitation, the results provide insight into the limited impact of these guidelines and current clinical variability in practice. The majority of the general gastrointestinal specialists (64.1%) were unaware of any published practice guidelines, compared with 33.3% of EUS specialists (P < 0.001). Management based upon clinical vignettes demonstrated moderate consistency with guidelines, appropriately answering 66.7% of the questions. For 9-mm cysts, only 25% of the questions were answered consistent with guidelines. Interestingly, EUS specialists were less likely to refer main-duct IPMNs for surgery and more likely to opt for EUS-FNA for branch-duct IPMNs (P < 0.001). The authors speculate EUS specialists favor EUS for evaluation and management because this is the skill they possess. Reliance on FNA results, or the ability to detect certain 'concerning features' by EUS (e.g. mural nodule), may afford an endosonographer confidence in the decision to delay surgical referral or continue with surveillance. Conversely, for those physicians who are less familiar with the capabilities of EUS or who practice in an area in which EUS is less accessible, they may be more likely to rely upon other imaging modalities or their local surgical expertise to manage such lesions of the pancreas. The International Association of Pancreatology (IAP) guidelines are currently being revised; this paper stresses that better dissemination of such 'expert' consensus documents is critically needed.
Despite concern of progression to malignancy in presumed neoplastic cysts, the increasing prevalence of incidental, asymptomatic lesions, many in elderly patients with comorbid diseases, calls into question the risk benefit of prophylactic surgery. As there are no controlled trials (and likely never to be) on the optimal management of patients with asymptomatic, incidental cystic lesions, investigators from the Mayo Clinic, Scottsdate turned to decision to compare different hypothetical management strategies to determine the most appropriate and cost-effective management of these patients [28 ] . Their goal was also to identify factors important in influencing clinical decisions, guiding future clinical investigation.
Three strategies were examined using a Markov model: natural history without intervention, resection, and EUS-FNA with cyst fluid analysis for risk stratification and mucinous cysts considered for resection. An operability risk score based on patient age, comorbidity, and size and location of the cyst was developed to estimate the probability of surgical resection. The model results suggested that the EUS-FNA strategy yielded the highest quality-adjusted life years with an acceptable incremental cost-effectiveness ratio. Not surprisingly, the operability risk score was the critical determinant of the optimal management strategy. This analysis supports the evolving approach advocating careful selection of asymptomatic patients with incidental pancreatic cystic neoplasms for surgery. Their results strongly challenge a blanket policy for surgical resection and advocate risk stratification for malignant potential by EUS-FNA and cyst fluid analysis.
Given the uncertainty of preoperative diagnosis and the morbidity and mortality of surgery, investigators have explored the safety and potential utility for ablation of the cysts with nonsurgical means. In a pilot study, 25 patients underwent EUS-guided pancreatic cyst lavage with ethanol concentrations as high as 80% with varying degrees of histologic epithelial ablation with cyst resolution in eight (35%) patients [29] . To further explore the utility and safety of this approach, EUS-guided ethanol lavage was compared with saline lavage in a prospective trial [30 ] . Patients referred for EUS with a 1-5-cm unilocular pancreatic cyst were randomized to blinded ethanol or saline solution lavage. Cysts with possible main pancreatic duct communication were excluded. Three months later, a second unblinded ethanol lavage was performed. Ethanol lavage resulted in a greater decrease in cyst surface area (À42.9%) compared with saline solution (À11.4%, P < 0.009). Nineteen (76.0%) of 25 and 14 (82.3%) of 17 patients randomized to ethanol and saline solution, respectively, underwent a second ethanol lavage. A follow-up CT scan demonstrated resolution in 12 (33.3%) of 36 cysts. Histology of four resected cysts demonstrated epithelial ablation ranging from 0% (saline solution alone) to 50-100%. Complication rates were noted as similar by the investigators (20% abdominal pain in ethanol and 11.8% in saline groups. However, acute pancreatitis occurred in one patient treated with ethanol lavage after treatment of a 1.1-cm cyst in the pancreatic head requiring a 10-day hospitalization. Major limitations of this study include the inclusion of presumed SCAs as well as pseudocysts. The authors' conclusion, that a single EUS-guided lavage of 80% ethanol resulted in a statistically greater mean decrease in pancreatic cyst size compared with a single saline solution injection, was clearly demonstrated. However, the clinical utility of short-term evidence of cyst ablation in 33% and variable histopathologic degrees of cyst epithelial ablation remains of dubious value. We agree that future research investigating the safety of this procedure, modifications of the technique, choice, and number of the lavage agents used (other studies have used paclitaxel for example), is needed. Most importantly, criteria to optimize selection of the appropriate pancreatic cysts for such treatment is essential, given the viability of surveillance and the evolving data supporting EUS with or without FNA for risk stratification.
A proposed management approach
Given the explosion in cystic lesion identification, a selective approach to detailed testing and surgical intervention is essential to improve outcomes as well as Our approach is summarized in Fig. 3 and summarized as follows. The approach to the patient begins with a detailed history looking for symptoms related to the lesion itself or a related condition such as pancreatitis. Fit patients with symptomatic lesions (not characterized as pseudocysts) usually proceed to surgery. Most asymptomatic patients have lesions too small to cause symptoms. Typical symptoms of malignancy are usually absent. Clinical decision-making is driven by an understanding of the differential diagnosis of the cyst and, in the case of the asymptomatic patient, its likelihood of causing harm with intervention.
Conclusion
The fundamental issue to be addressed is whether the cyst is neoplastic or not, and if so, what is its risk for malignant degeneration. In the absence of a history of pancreatitis, pseudocyst is quite unlikely (but not impossible), and the concern of a cystic neoplasm is paramount. If preoperative characterization of the lesion will change management, EUS with or without FNA for cytology and fluid analysis may provide information of diagnostic and prognostic value. For those patients with benign-appearing lesions, such as those with a classic appearance of a SCA, a decision regarding the patient's willingness to observe the lesion should be developed in collaboration with a pancreatic surgeon. In many circumstances, selected use of EUS with or without FNA with cytology and fluid measurement can further provide evidence to support the approach of watchful waiting. Patients can then be carefully monitored with serial examinations (EUS or less invasive cross-sectional imaging) to exclude change in size. Watchful waiting clearly represents a carefully considered trade-off between delayed surgery for unresectable disease and unnecessary surgical morbidity and mortality.
